Regenerative approaches deliver up to 3x better results than traditional treatments
Mumbai, 4th May 2026: Hair loss may finally be moving beyond temporary fixes to true biological reversal. A new scientific paper titled “Activation of Bulge Stem Cells through Mechano-Stimulation and ECM Remodeling: Emerging Paradigms in Hair Follicle Regeneration,” published in Stem Cell Reviews and Reports, reveals that hair loss may be reversible by targeting its biological root cause. The research highlights that baldness is driven not just by hair fall, but by dormant stem cells trapped in a stiff, damaged scalp environment. By combining mechanical stimulation techniques such as microneedling, wearable stretchers and vibration with extracellular matrix (ECM) repair, scientists have demonstrated that these “sleeping” stem cells can be reactivated leading to natural hair regrowth without reliance on drugs.
Clinical findings show up to 20–30% improvement in hair density within just 12 weeks, while advanced regenerative approaches outperform traditional treatments by 3x. The breakthrough reframes hair loss treatment entirely from managing symptoms to restoring the biology of hair growth at its source, opening up a new frontier in regenerative dermatology.
Dr. Rinky Kapoor, Clinical Scientist and Research Mentor, QR678®, said, “Today’s hair loss market is dominated by solutions that largely address symptoms rather than the underlying biology. This research changes that paradigm by targeting the root cause, reactivating dormant stem cells and restoring the scalp environment. It offers a fundamentally new approach that moves us closer to long-term, sustainable hair regeneration.”
Dr. Raji Patil, Head of Medical Affairs, QR678® added, “This study is significant because it brings together mechano-biology and regenerative science in a way that has not been done before in hair research. By demonstrating how mechanical forces and ECM remodelling directly influence stem cell activation pathways like Wnt and YAP/TAZ, it lays a strong scientific foundation for next-generation therapies. Its relevance extends beyond hair loss, potentially impacting broader regenerative medicine applications.”
Dr. Mamata Mishra, Clinical Research, QR678®, added, “This research represents a shift toward next-generation regenerative therapies that work with the body’s own biology rather than relying on external or symptomatic interventions. It sets the stage for more advanced, personalized approaches to hair restoration in the future.”
As research advances, this approach could redefine how hair loss is treated globally, shifting from lifelong dependency on topical or pharmaceutical solutions to precision-driven, biology-first regeneration, where the focus is not just on growing hair, but restoring the system that creates it.
About QR678®
QR678® is a clinically developed, non-surgical hair regeneration therapy platform based on growth factor science and regenerative dermatology. Developed to address common forms of hair loss, such as androgenetic alopecia and telogen effluvium, the platform delivers products with a targeted combination of biomimetic peptides and growth factors into the scalp to support follicular function, improve hair density, and enhance hair thickness.
Over the years, the QR678® platform has released multiple products globally which offer standardised treatments for hair loss, reducing the variability associated with patient-derived treatments. Administered by trained medical professionals, QR678® platform derived therapies are minimally invasive and positioned within a broader shift toward precision-driven, reproducible approaches in hair restoration.
